ftInvstr
THYROCARE · Healthcare ₹576.4 -0.28% Mkt Cap ₹9179 Cr overvalued

THYROCARE

Healthcare Diagnostics & Research
₹576.4
-0.28% today · 30d -4.54%
as of 2026-09-04
Price · Daily Candles
“Thyrocare's fortunes flip: Robust profit surge fuels a 58% rally, defying a bonus issue dilution.”
Thyrocare Technologies reported a significant turnaround in its Q4 2026 results with net profit soaring 125.78% YoY to ₹49 Cr and annual net profit up 79.45% to ₹163 Cr. This strong performance, alongside a 58.0% one-year price return, comes after a 2:1 bonus issue in November 2025.
BULL CASE
+Q4 2026 net profit surged by a remarkable 125.78% YoY to ₹49 Cr, showcasing strong operational leverage.
+Annual net profit for FY26 increased by 79.45% YoY to ₹163 Cr, complementing a 20.61% rise in annual revenue to ₹829 Cr.
+Operating profit margin (OPM) saw a 2.3 percentage point increase YoY in Q4 2026, reaching 34.78%.
+Return on Capital Employed (RoCE) stands at 37.0%, comparing favorably to peers like Metropolis (20.67%) and Dr. Lal PathLabs (34.14%).
+FIIs and DIIs both increased their stakes QoQ by 0.42% and 0.48% respectively in Q4 2026.
BEAR CASE
The stock is trading 6.46% below its 52-week high of ₹536.67, despite strong recent returns.
The 3-month share price return of 20.2% significantly underperformed its 1-month return of 27.06%, indicating recent acceleration but prior weakness.
ML predictions for Free Cash Flow (FCF) growth show a weak ranking, with future negative FCF expected (e.g., -44.2% in h1 of recent 2y model).
Despite strong profitability, the stock's P/E (TTM) of 48.95 is above its forward P/E of 36.79, suggesting some growth is already priced in.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹240 Cr
+24.34% YoY
NET PROFIT
₹51 Cr
+34.06% YoY
OPM
33.35%
+1.77pp YoY
EPS
₹3.23
PE 48.95
Intrinsic value · DCF ₹29.74 · Margin of safety -94.8% (overvalued) · FCF yield 2.1%
◇ Sector Position
Thyrocare, with a P/E of 48.95 and RoCE of 37.0%, demonstrates strong profitability compared to peers like Dr. Lal PathLabs (P/E 53.06, RoCE 34.14%) and Metropolis (P/E 59.01, RoCE 20.67%).
PEERPEROCE %
THYROCARE48.9537.0
LALPATHLAB53.0634.14
SAILIFE69.3718.42
SYNGENE59.0321.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
75
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 90
Valuation FAIR 40
Growth STRONG 81
Profitability HIGH 95
Technicals NEUTRAL 62
Risk LOW 80
Key Stats
TTM PE
48.95
P/B
14.95
52W HIGH
₹662.0
OFF HIGH
-12.93%
DIV YIELD
1.89%
MKT CAP
₹9179 Cr
◉ Active Signals
MACDNeutral-4.2921
RSI(14)Neutral46.72
Street Consensus
4 analysts
₹600.0
mean target
Low ₹550.0Now ₹576.4High ₹650.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold THYROCARE and at what entry.

Sign up freeSign in